In a patient with stage III NSCLC who was treated with neoadjuvant systemic therapy and had a PR, would you deliver RT to all sites of initially involved disease, or only residual sites of disease?  

E.g. If a patient had CR in the primary tumor but PR in the nodes, would you still treat the primary? 



Answer from: Radiation Oncologist at Academic Institution